重视晚期肝癌肝功能状态对免疫检查点抑制剂疗效的评估

摘要/Abstract

摘要： 原发性肝癌(PLC)是2020年全球第六大最常见癌症,死亡率高居不下,其中肝细胞癌(HCC)占75%~85%。由于早期症状不明显,临床上,相当一部分的HCC患者确诊时已是中晚期,治疗方法有限,近年来,免疫检查点抑制剂(ICIs)的出现为这部分患者提供了新的选择。而大部分HCC患者均有不同程度的慢性肝病背景,故HCC的进展状态和肝功能状态是影响患者死亡风险的两大主要因素。而在接受免疫检查点抑制剂治疗的晚期HCC患者中,重视评估肝功能状态,通过对肝病病因、既往或当前的肝硬化失代偿状态、门静脉高压的严重程度和HCC进展以及肝功能状态等情况进行综合评估,富集可从免疫检查点抑制剂系统性治疗中获益的亚群,以评估治疗的风险-效益比,进行精准治疗,从而提升肝功能状态欠佳的部分晚期HCC患者的疗效。

关键词: 肝细胞癌, 免疫检查点抑制剂, 肝功能, Child-Pugh分级, ALBI评分

王庆, 范芯铷, 汪慧. 重视晚期肝癌肝功能状态对免疫检查点抑制剂疗效的评估[J]. 肝脏, 2023, 28(7): 751-752.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3):209-249.
[2] Garrido A, Djouder N. Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma. Trends Cancer, 2021, 7 (1): 29-36.
[3] Cabibbo G, Petta S, Barbara M, et al; Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol, 2017, 67 (1):65-71.
[4] Iavarone M, Cabibbo G, Piscaglia F, et al; SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology, 2011, 54 (6):2055-2063.
[5] Iavarone M, Cabibbo G, Biolato M, et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology, 2015, 62(3):784-791.
[6] Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol, 2021, 74 (5):1225-1233.
[7] Peng Y, Wei Q, He Y, et al. ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review. Expert Rev Gastroenterol Hepatol, 2020, 14(5):383-400.
[8] 中华医学会肝病学分会.肝硬化诊治指南. 临床肝胆病杂志, 2019, 35(11): 2408-2425.
[9] Kok B, Abraldes JG. Child-Pugh Classification: Time to Abandon? Semin Liver Dis, 2019, 39(1):96-103.
[10] Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol, 2015, 33(6):550-558.
[11] Demirtas CO, D'Alessio A, Rimassa L, et al. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep, 2021, 3(5):100347.
[12] Bannaga A, Arasaradnam RP. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. World J Gastroenterol, 2020, 26(33):5022-5049.
[13] Tian BW, Yan LJ, Ding ZN, Liu H, et al. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis. Int Immunopharmacol, 2023.
[14] Ruf A, Dirchwolf M, Freeman RB. From Child-Pugh to MELD score and beyond: Taking a walk down memory lane. Ann Hepatol, 2022, 27(1):100535.
[15] Common Terminology Criteria for Adverse Events (CTCAE) Version 5. November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
[16] El Hajra I, Sanduzzi-Zamparelli M, Sapena V, et al. Outcome of patients with hepatocellular carcinoma and liver dysfunction under immunotherapy: a Systematic review and meta-analysis. Hepatology, 2023, 77 (4):1139-1149
[17] Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol, 2021, 75 (3):600-609.
[18] Concato J, Corrigan-Curay J. Real-World Evidence-Where Are We Now? N Engl J Med, 2022, 386(18):1680-1682.